Is the cost-effectiveness threshold cost-effective in cancer therapy?
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2015, Vol 8, Issue 2
Abstract
Introduction: To compare availability of innovative cancer drugs in countries with established cost-effectiveness threshold (Great Britain, Czech Republic, Sweden and Poland) and where this criterion is not used (Germany, France, Italy), and to assess the relationship between the reimbursement system and the expenditures and health outcomes. Methods: The analysis of reimbursement decisions concerning innovative cancer drugs approved by the European Medicines Agency in the years 2012-2013 and the available data concerning incidence, 5-year relative survival rate and the treatment costs of breast, lung, colon and prostate cancer. Results: The assessment included 19 innovative drugs. Most of them were covered by reimbursement in countries without a cost-effectiveness threshold — 80.7%, compared to the countries with a cost-effectiveness threshold — 59.6% (48.7% including Poland). Three products were financed in all reimbursement systems, with the exception of Poland: Perjeta, Xalkori and Xtandi. In countries without the cost-effectiveness threshold the health outcomes expressed as 5-year relative survival were better compared to EU in general or to most of countries which use the cost-effectiveness threshold, whereas expenditures per capita in most cancers were diversified — large (15-27 €, Germany) or similar to the countries with the cost-effectiveness threshold (6-13 €, France and Italy). In Poland for most evaluated cancers the lowest 5-year relative survival was noted, with the lowest expenditure per capita (5-9 €) simultaneously. Conclusions: The percentage of reimbursed innovative cancer drugs is higher in countries without the cost-effectiveness threshold, where better health outcomes are observed. Limited access to innovative therapies resulting from restrictive financial criteria may have a significant impact on health outcomes in cancer treatment.
Authors and Affiliations
Łukasz Kaczyński, Beata Serafin, Patrycja Prząda-Machno, Marcin Kaczor
Keywords
Related Articles
- EP ID EP192167
- DOI 10.7365/JHPOR.2015.2.6
- Views 118
- Downloads 0
Approach to uncertainty in health technology assessment in a Central and Eastern European country: appraisal of cancer drugs by a Polish HTA agency in presence of high crossover rates in clinical trials
Background: Health technology assessment (HTA) plays an important role in reimbursement decision making in Poland and its principles are similar to those used in other countries. However, specific inter-country differenc...
Treatment options in chronic lymphocytic leukemia (CLL) – a Polish perspective
Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia among the elderly people in Western societies. CLL is genetically and molecularly heterogeneous disease that translates into clinical outcomes. Cur...
Aging society: organization of long-term care for the elderly in Poland.
Background: Aging society is one of the main challenges of the organization and provision of health care in XXI century. In 2030 more than one third of Polish population will be older than 65 years old and every tenth...
Idiopathic Pulmonary Fibrosis as a Challenge for the Polish Healthcare System
Idiopathic pulmonary fibrosis (IPF) is a rare disease characterised by age-dependent incidence, unclear aetiology and progressive course. Given the complexity of the diagnostic pathway and limited therapeutic options, an...
Cancer immunotherapy in second-line treatment of non-small cell lung cancer – is there a need to change the approach to the assessment of clinical benefits?
Background: The mechanism of action distinctive for immunotherapy leads to the specific pattern of tumour response, different form the one observed with cytotoxic therapy. To enable a complete assessment of immunotherape...